Cytokines: Interleukins and tumournecrosis factor - Pharmaceutical Biotechnology: Concepts and Aapplications - page 265

Renauld, J.C., Kermouni, A., Vink, A., Louahed, J., and Van Snick, J. 1995. Interleukin-9 and its receptor: in-
volvement in mast cell differentiation and T-cell oncogenesis. Journal of Leukocyte Biology 57 , 353-359.
Ryan, J. 1997. Interleukin-4 and its receptor - essential mediators of the allergic response. Journal of Allergy and
Clinical Immunology 99 (1), 1-5.
Simpson, R.J., Hammacher, A., Smith, D.K., Matthews, J.M., and Ward, L.D. 1997. Interleukin-6 structure—
function relationships. Protein Science , 6 (5), 929-955.
Scott, P. 1993. IL-12: initiation cytokine for cell mediated immunity. Science 260 , 496-497.
Wigginton, J. and Wiltrout, R. 2002 IL-12/IL-2 combination cytokine therapy for solid tumors: translation from
benchside to bedside. Expert Opinion on Biological Therapy 2 (5), 513-524.
Tumour necrosi s factor
Argiles, J. and Lepezsoriano, F. 1997. Cancer cachexia - a key role for TNF. International Journal of Oncology
10 (3), 565-572.
Bodmer, J.-L., Schneider, P., and Tschopp, J. 2002. The molecular architecture of the TNF superfamily. Tren ds
in Biochemical Sciences 27 (1), 19-26.
Bondeson, J., Feldmann, M., and Maini, R.N. 2001. Tumour necrosis factor as a therapeutic target: from the
laboratory to the clinic. Immunologist 8 (6), 136-140.
Brandt, J. and Braun, J. 2006. Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opinion on
Biological Therapy 6 (2), 99-107.
Crowe, P.D., VanArsdale, T.L., Walter, B.N., Ware, C.F., Hession, C., Ehrenfels, B., Browning, J.L., Din, W.S.,
Goodwin, R.G., and Smith, C.A. 1994. A lymphotoxin-β-specifi c receptor. Science 264 , 707-709.
Darnay, B. and Aggarwal, B. 1997. Early events in TNF signalling - a story of associations and disassociations.
Journal of Leukocyte Biology 61 (5), 559-566.
Dellinger, R.P., Opal, S.M., Rotrosen, D., Suffredini, A.F., and Zimmerman, J.L. 1997. From the bench to the
bedside - the future of sepsis research. Chest 111 (3), 744-753.
Feldmann, M., Elliott, M.J., Woody, J.N., Maini, R.N. 1997. Anti-tumor necrosis factor alpha therapy of rheuma-
toid arthritis. Advances in Immunology 64 , 283-350.
Liu, Z. 2005. Molecular mechanism of TNF signaling and beyond. Cell Research 15 (1), 24 -27.
MacEwan, D. 2002. TNF receptor subtype signalling: differences and cellular consequences. Cellular Signalling
14 (6), 477-492.
McDermot, M. 2001. TNF and TNFR biology in health and disease. Cellular and Molecular Biology 47 (4),
619 - 635.
Moreland, L.W., Heck, L.W., and Koopman, W.J. 1997. Biologic agents for treating rheumatod arthritis: concepts
and progress. Arthritis and Rheumatism 40 (3), 397-409.
McGeer, E. and McGeer, P. 1997. Infl ammatory cytokines in the CNS - possible role in the pathogenesis of neu-
rodegenerative disorders and therapeutic implications. CNS Drugs 7 (3), 214-228.
Nestorov, I. 2005. Clinical pharmacokinetics of TNF antagonists: how do they differ? Seminars in Arthritis and
Rheumatism 34 (5)(Suppl. 1), 12-19.
Pestka, S., Krause, C.D., Sarkar, D., Walter, M.R., Shi, Y., and Fisher, P.B. 2004 Interleukin-10 and related
cytokines and receptors. Annual Review of Immunology 22 , 929-979.
Terranova, P. 1997. Potential roles of tumor necrosis factor-alpha in follicular development, ovulation and the
life-span of the corpus luteum. Domestic Animal Endocrinology 14 (1), 1-15.
Tracey, K. and Cerami, A. 1994. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annual
Review of Medicine 45 , 491-503.
Vandenabeele, P., Declercq, W., Beyaert, R., and Fiers, W. 1995. Two tumour necrosis factor receptors: structure
and function. Trends in Cell Biology 5 , 392-399.